All In Biotech

Drug Trial Radar · NCT04845399

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

A Single-Arm, Multicenter, Open-label Phase III Expansion Trial Evaluating Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Apr 16, 2021

Primary completion

Jun 26, 2021

Study completion Jun 26, 2021

Sponsor

Lead sponsor
Zhengzhou Gensciences IncIndustry
Sponsor type
Industry
Collaborators
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
First posted
Apr 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.

Conditions

  • Hemophilia A

Interventions

  • Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug

    Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleeding Rates (ABR).Time frame: For the duration of study participation, 6 months.
  2. Number of target joints.Time frame: For the duration of study participation, 6 months.
  3. Annualized Joint Bleeding Rate (AJBR)Time frame: For the duration of study participation, 6 months.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Capital Medical University affiliated Beijing Children's Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangzhou, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangzhou, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Henan provincial People's Hospital

    Zhengzhou, He'nan, China

  • Henan Cancer Hospital

    Zhengzhou, He'nan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical College

    Xuzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Jinan central hospital

    Ji'nan, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.